Final prespecified overall survival (OS) analysis of CLEAR: 4-year follow-up of lenvatinib plus pembrolizumab (L+P) vs sunitinib (S) in patients (pts) with advanced renal cell carcinoma (aRCC).

Overview of attention for article published in Journal of Clinical Oncology, May 2023

Altmetric Badge

About this Attention Score

In the top 5% of all research outputs scored by Altmetric
High Attention Score compared to outputs of the same age (95th percentile)
High Attention Score compared to outputs of the same age and source (90th percentile)

Mentioned by

news: 6 news outlets

guideline: 1 clinical guideline source

Readers on

mendeley: 18 Mendeley

So far, Altmetric has seen 15 news stories from 6 outlets.

Changes in Tumor Size Track Advanced RCC Outcomes, Analyses From CLEAR Show

AJMC, 11 Feb 2025

Changes in tumor size track outcomes for patients with advanced renal cell carcinoma (aRCC), according to new data from the…

Therapie des metastasierten Nierenzellkarzinoms

Deutsches Ärzteblatt, 22 Aug 2024

INTERNATIONAL STUDIEREN Artikel Autoren Grafiken/Tabellen Literatur Kommentare/Briefe Statistik Zitiert Hintergrund: Rund 15000…

Immunotherapy/TKI Combinations Yield Efficacy Benefit in RCC

Cancer Network, 02 Jan 2024

The expert panel Follow Wenxin Xu, MD, on his Morning Rounds with Patrick Curran, MSN, AGACNP, and Marina Kaymakcalan, PharmD…

Lenvatinib Plus Pembrolizumab Yields Continuous Efficacy in CLEAR Trial for Advanced RCC

Cancer Network, 13 Oct 2023

The panel discussed the phase 3 CLEAR trial (NCT02811861). During the 2023 Kidney Cancer Research Summit, experts in the field…

This page shows the most recent news stories that mention this research output. Click here to find out how to access more activity, including 11 additional news stories.